The Negative Effect of Triple-Negative Breast Cancer on Outcome after Breast-Conserving Therapy
Purpose To evaluate disease failure patterns and overall survival (OS) of women with triple-negative (TN) breast cancer who underwent breast-conserving therapy (BCT) and to understand the relationship of TN tumors with other prognostic factors. Patients and Methods The Surveillance, Epidemiology, an...
Gespeichert in:
| Veröffentlicht in: | Annals of surgical oncology 2011-10, Vol.18 (10), p.2858-2865 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2865 |
|---|---|
| container_issue | 10 |
| container_start_page | 2858 |
| container_title | Annals of surgical oncology |
| container_volume | 18 |
| creator | Zaky, Sandra S. Lund, MaryJo May, Kelly A. Godette, Karen D. Beitler, Jonathan J. Holmes, Leslie R. O’Regan, Ruth M. Yu, Esther S. Yu, David S. Landry, Jerome C. |
| description | Purpose
To evaluate disease failure patterns and overall survival (OS) of women with triple-negative (TN) breast cancer who underwent breast-conserving therapy (BCT) and to understand the relationship of TN tumors with other prognostic factors.
Patients and Methods
The Surveillance, Epidemiology, and End Results (SEER) registry identified 562 women diagnosed and/or treated with unilateral invasive breast cancer during 2003–2004 at three Emory hospitals. After medical record review, 193 eligible women, with all tumor types, received BCT. Primary endpoints (local, regional, and distant recurrences) and secondary endpoint (OS) were evaluated using chi-square tests and Cox proportional hazards models.
Results
Of the 193 women, 33 (17.1%) had TN tumors and 160 (82.9%) had non-TN tumors. Patient characteristics were similar between the two tumor types; however, tumor grade and use of chemotherapy and hormones differed between the two groups. Median follow-up was 3.4 years; 22 patients had recurrence (12.2%), and 12 died (6.2%). Patients with TN tumors had higher local (12% versus 4% for non-TN) and distant recurrences (15% versus 4% for non-TN) rates (
p
= 0.01). On multivariate survival analyses, TN status [hazard ratio (HR) 1.8, 95% confidence interval (CI) 1.13–2.93] and African American (AA) race (HR 1.9, 95%CI 1.2–3.07) were independent predictors of inferior OS.
Conclusions
Patients with TN breast cancer showed significant increases in local and distant metastatic recurrence rates after BCT, and TN status and AA race were independent negative predictors of survival. For the future, identification of these high risk features may bring personalized medicine closer to reality. |
| doi_str_mv | 10.1245/s10434-011-1669-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_889445708</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2449661011</sourcerecordid><originalsourceid>FETCH-LOGICAL-c370t-61802cae3aacd9af4ff2208f584b23ffdf016b0d611ea51d4d970566e903e49c3</originalsourceid><addsrcrecordid>eNp1kMFO3DAQhi3Uqrts-wBckMWFk9sZx3GcYxsBrYTKZXu2vM54CdpNtnaCtG-PUYBKSD3Zmv-b39bH2BnCV5Sq_JYQVKEEIArUuhbqhC2xzBOlDX7Id9BG1FKXC3aa0gMAVgWUn9hColKyUHrJ7Pqe-G_aurF7JH4VAvmRD4GvY3fYkXhLfkRyaeSN6z1FPvT8bhr9sCfuwpgHcyyaoU8UH7t-y3NvdIfjZ_YxuF2iLy_niv25vlo3P8Xt3c2v5vut8EUFo9BoQHpHhXO-rV1QIUgJJpRGbWQRQhsA9QZajUiuxFa1dQWl1lRDQar2xYpdzr2HOPydKI123yVPu53raZiSNaZWqqzAZPLiHfkwTLHPn8uQqUDLbGnFcIZ8HFKKFOwhdnsXjxbBPru3s3ub3dtn91blnfOX4mmzp_Zt41V2BuQMpBz1W4r_Xv5_6xNsEo5D</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>888706217</pqid></control><display><type>article</type><title>The Negative Effect of Triple-Negative Breast Cancer on Outcome after Breast-Conserving Therapy</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Zaky, Sandra S. ; Lund, MaryJo ; May, Kelly A. ; Godette, Karen D. ; Beitler, Jonathan J. ; Holmes, Leslie R. ; O’Regan, Ruth M. ; Yu, Esther S. ; Yu, David S. ; Landry, Jerome C.</creator><creatorcontrib>Zaky, Sandra S. ; Lund, MaryJo ; May, Kelly A. ; Godette, Karen D. ; Beitler, Jonathan J. ; Holmes, Leslie R. ; O’Regan, Ruth M. ; Yu, Esther S. ; Yu, David S. ; Landry, Jerome C.</creatorcontrib><description>Purpose
To evaluate disease failure patterns and overall survival (OS) of women with triple-negative (TN) breast cancer who underwent breast-conserving therapy (BCT) and to understand the relationship of TN tumors with other prognostic factors.
Patients and Methods
The Surveillance, Epidemiology, and End Results (SEER) registry identified 562 women diagnosed and/or treated with unilateral invasive breast cancer during 2003–2004 at three Emory hospitals. After medical record review, 193 eligible women, with all tumor types, received BCT. Primary endpoints (local, regional, and distant recurrences) and secondary endpoint (OS) were evaluated using chi-square tests and Cox proportional hazards models.
Results
Of the 193 women, 33 (17.1%) had TN tumors and 160 (82.9%) had non-TN tumors. Patient characteristics were similar between the two tumor types; however, tumor grade and use of chemotherapy and hormones differed between the two groups. Median follow-up was 3.4 years; 22 patients had recurrence (12.2%), and 12 died (6.2%). Patients with TN tumors had higher local (12% versus 4% for non-TN) and distant recurrences (15% versus 4% for non-TN) rates (
p
= 0.01). On multivariate survival analyses, TN status [hazard ratio (HR) 1.8, 95% confidence interval (CI) 1.13–2.93] and African American (AA) race (HR 1.9, 95%CI 1.2–3.07) were independent predictors of inferior OS.
Conclusions
Patients with TN breast cancer showed significant increases in local and distant metastatic recurrence rates after BCT, and TN status and AA race were independent negative predictors of survival. For the future, identification of these high risk features may bring personalized medicine closer to reality.</description><identifier>ISSN: 1068-9265</identifier><identifier>EISSN: 1534-4681</identifier><identifier>DOI: 10.1245/s10434-011-1669-4</identifier><identifier>PMID: 21442346</identifier><language>eng</language><publisher>New York: Springer-Verlag</publisher><subject>Antineoplastic Agents - therapeutic use ; Breast Neoplasms - metabolism ; Breast Neoplasms - mortality ; Breast Neoplasms - therapy ; Breast Oncology ; Combined Modality Therapy ; Female ; Follow-Up Studies ; Humans ; Medicine ; Medicine & Public Health ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Recurrence, Local - metabolism ; Neoplasm Recurrence, Local - mortality ; Neoplasm Recurrence, Local - therapy ; Oncology ; Receptor, ErbB-2 - metabolism ; Receptors, Estrogen - metabolism ; Receptors, Progesterone - metabolism ; Retrospective Studies ; SEER Program ; Surgery ; Surgical Oncology ; Survival Rate ; Treatment Outcome</subject><ispartof>Annals of surgical oncology, 2011-10, Vol.18 (10), p.2858-2865</ispartof><rights>Society of Surgical Oncology 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c370t-61802cae3aacd9af4ff2208f584b23ffdf016b0d611ea51d4d970566e903e49c3</citedby><cites>FETCH-LOGICAL-c370t-61802cae3aacd9af4ff2208f584b23ffdf016b0d611ea51d4d970566e903e49c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1245/s10434-011-1669-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1245/s10434-011-1669-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27922,27923,41486,42555,51317</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21442346$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zaky, Sandra S.</creatorcontrib><creatorcontrib>Lund, MaryJo</creatorcontrib><creatorcontrib>May, Kelly A.</creatorcontrib><creatorcontrib>Godette, Karen D.</creatorcontrib><creatorcontrib>Beitler, Jonathan J.</creatorcontrib><creatorcontrib>Holmes, Leslie R.</creatorcontrib><creatorcontrib>O’Regan, Ruth M.</creatorcontrib><creatorcontrib>Yu, Esther S.</creatorcontrib><creatorcontrib>Yu, David S.</creatorcontrib><creatorcontrib>Landry, Jerome C.</creatorcontrib><title>The Negative Effect of Triple-Negative Breast Cancer on Outcome after Breast-Conserving Therapy</title><title>Annals of surgical oncology</title><addtitle>Ann Surg Oncol</addtitle><addtitle>Ann Surg Oncol</addtitle><description>Purpose
To evaluate disease failure patterns and overall survival (OS) of women with triple-negative (TN) breast cancer who underwent breast-conserving therapy (BCT) and to understand the relationship of TN tumors with other prognostic factors.
Patients and Methods
The Surveillance, Epidemiology, and End Results (SEER) registry identified 562 women diagnosed and/or treated with unilateral invasive breast cancer during 2003–2004 at three Emory hospitals. After medical record review, 193 eligible women, with all tumor types, received BCT. Primary endpoints (local, regional, and distant recurrences) and secondary endpoint (OS) were evaluated using chi-square tests and Cox proportional hazards models.
Results
Of the 193 women, 33 (17.1%) had TN tumors and 160 (82.9%) had non-TN tumors. Patient characteristics were similar between the two tumor types; however, tumor grade and use of chemotherapy and hormones differed between the two groups. Median follow-up was 3.4 years; 22 patients had recurrence (12.2%), and 12 died (6.2%). Patients with TN tumors had higher local (12% versus 4% for non-TN) and distant recurrences (15% versus 4% for non-TN) rates (
p
= 0.01). On multivariate survival analyses, TN status [hazard ratio (HR) 1.8, 95% confidence interval (CI) 1.13–2.93] and African American (AA) race (HR 1.9, 95%CI 1.2–3.07) were independent predictors of inferior OS.
Conclusions
Patients with TN breast cancer showed significant increases in local and distant metastatic recurrence rates after BCT, and TN status and AA race were independent negative predictors of survival. For the future, identification of these high risk features may bring personalized medicine closer to reality.</description><subject>Antineoplastic Agents - therapeutic use</subject><subject>Breast Neoplasms - metabolism</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - therapy</subject><subject>Breast Oncology</subject><subject>Combined Modality Therapy</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neoadjuvant Therapy</subject><subject>Neoplasm Recurrence, Local - metabolism</subject><subject>Neoplasm Recurrence, Local - mortality</subject><subject>Neoplasm Recurrence, Local - therapy</subject><subject>Oncology</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Receptors, Estrogen - metabolism</subject><subject>Receptors, Progesterone - metabolism</subject><subject>Retrospective Studies</subject><subject>SEER Program</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><issn>1068-9265</issn><issn>1534-4681</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kMFO3DAQhi3Uqrts-wBckMWFk9sZx3GcYxsBrYTKZXu2vM54CdpNtnaCtG-PUYBKSD3Zmv-b39bH2BnCV5Sq_JYQVKEEIArUuhbqhC2xzBOlDX7Id9BG1FKXC3aa0gMAVgWUn9hColKyUHrJ7Pqe-G_aurF7JH4VAvmRD4GvY3fYkXhLfkRyaeSN6z1FPvT8bhr9sCfuwpgHcyyaoU8UH7t-y3NvdIfjZ_YxuF2iLy_niv25vlo3P8Xt3c2v5vut8EUFo9BoQHpHhXO-rV1QIUgJJpRGbWQRQhsA9QZajUiuxFa1dQWl1lRDQar2xYpdzr2HOPydKI123yVPu53raZiSNaZWqqzAZPLiHfkwTLHPn8uQqUDLbGnFcIZ8HFKKFOwhdnsXjxbBPru3s3ub3dtn91blnfOX4mmzp_Zt41V2BuQMpBz1W4r_Xv5_6xNsEo5D</recordid><startdate>20111001</startdate><enddate>20111001</enddate><creator>Zaky, Sandra S.</creator><creator>Lund, MaryJo</creator><creator>May, Kelly A.</creator><creator>Godette, Karen D.</creator><creator>Beitler, Jonathan J.</creator><creator>Holmes, Leslie R.</creator><creator>O’Regan, Ruth M.</creator><creator>Yu, Esther S.</creator><creator>Yu, David S.</creator><creator>Landry, Jerome C.</creator><general>Springer-Verlag</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20111001</creationdate><title>The Negative Effect of Triple-Negative Breast Cancer on Outcome after Breast-Conserving Therapy</title><author>Zaky, Sandra S. ; Lund, MaryJo ; May, Kelly A. ; Godette, Karen D. ; Beitler, Jonathan J. ; Holmes, Leslie R. ; O’Regan, Ruth M. ; Yu, Esther S. ; Yu, David S. ; Landry, Jerome C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c370t-61802cae3aacd9af4ff2208f584b23ffdf016b0d611ea51d4d970566e903e49c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Antineoplastic Agents - therapeutic use</topic><topic>Breast Neoplasms - metabolism</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - therapy</topic><topic>Breast Oncology</topic><topic>Combined Modality Therapy</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neoadjuvant Therapy</topic><topic>Neoplasm Recurrence, Local - metabolism</topic><topic>Neoplasm Recurrence, Local - mortality</topic><topic>Neoplasm Recurrence, Local - therapy</topic><topic>Oncology</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Receptors, Estrogen - metabolism</topic><topic>Receptors, Progesterone - metabolism</topic><topic>Retrospective Studies</topic><topic>SEER Program</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zaky, Sandra S.</creatorcontrib><creatorcontrib>Lund, MaryJo</creatorcontrib><creatorcontrib>May, Kelly A.</creatorcontrib><creatorcontrib>Godette, Karen D.</creatorcontrib><creatorcontrib>Beitler, Jonathan J.</creatorcontrib><creatorcontrib>Holmes, Leslie R.</creatorcontrib><creatorcontrib>O’Regan, Ruth M.</creatorcontrib><creatorcontrib>Yu, Esther S.</creatorcontrib><creatorcontrib>Yu, David S.</creatorcontrib><creatorcontrib>Landry, Jerome C.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zaky, Sandra S.</au><au>Lund, MaryJo</au><au>May, Kelly A.</au><au>Godette, Karen D.</au><au>Beitler, Jonathan J.</au><au>Holmes, Leslie R.</au><au>O’Regan, Ruth M.</au><au>Yu, Esther S.</au><au>Yu, David S.</au><au>Landry, Jerome C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Negative Effect of Triple-Negative Breast Cancer on Outcome after Breast-Conserving Therapy</atitle><jtitle>Annals of surgical oncology</jtitle><stitle>Ann Surg Oncol</stitle><addtitle>Ann Surg Oncol</addtitle><date>2011-10-01</date><risdate>2011</risdate><volume>18</volume><issue>10</issue><spage>2858</spage><epage>2865</epage><pages>2858-2865</pages><issn>1068-9265</issn><eissn>1534-4681</eissn><abstract>Purpose
To evaluate disease failure patterns and overall survival (OS) of women with triple-negative (TN) breast cancer who underwent breast-conserving therapy (BCT) and to understand the relationship of TN tumors with other prognostic factors.
Patients and Methods
The Surveillance, Epidemiology, and End Results (SEER) registry identified 562 women diagnosed and/or treated with unilateral invasive breast cancer during 2003–2004 at three Emory hospitals. After medical record review, 193 eligible women, with all tumor types, received BCT. Primary endpoints (local, regional, and distant recurrences) and secondary endpoint (OS) were evaluated using chi-square tests and Cox proportional hazards models.
Results
Of the 193 women, 33 (17.1%) had TN tumors and 160 (82.9%) had non-TN tumors. Patient characteristics were similar between the two tumor types; however, tumor grade and use of chemotherapy and hormones differed between the two groups. Median follow-up was 3.4 years; 22 patients had recurrence (12.2%), and 12 died (6.2%). Patients with TN tumors had higher local (12% versus 4% for non-TN) and distant recurrences (15% versus 4% for non-TN) rates (
p
= 0.01). On multivariate survival analyses, TN status [hazard ratio (HR) 1.8, 95% confidence interval (CI) 1.13–2.93] and African American (AA) race (HR 1.9, 95%CI 1.2–3.07) were independent predictors of inferior OS.
Conclusions
Patients with TN breast cancer showed significant increases in local and distant metastatic recurrence rates after BCT, and TN status and AA race were independent negative predictors of survival. For the future, identification of these high risk features may bring personalized medicine closer to reality.</abstract><cop>New York</cop><pub>Springer-Verlag</pub><pmid>21442346</pmid><doi>10.1245/s10434-011-1669-4</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1068-9265 |
| ispartof | Annals of surgical oncology, 2011-10, Vol.18 (10), p.2858-2865 |
| issn | 1068-9265 1534-4681 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_889445708 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Antineoplastic Agents - therapeutic use Breast Neoplasms - metabolism Breast Neoplasms - mortality Breast Neoplasms - therapy Breast Oncology Combined Modality Therapy Female Follow-Up Studies Humans Medicine Medicine & Public Health Middle Aged Neoadjuvant Therapy Neoplasm Recurrence, Local - metabolism Neoplasm Recurrence, Local - mortality Neoplasm Recurrence, Local - therapy Oncology Receptor, ErbB-2 - metabolism Receptors, Estrogen - metabolism Receptors, Progesterone - metabolism Retrospective Studies SEER Program Surgery Surgical Oncology Survival Rate Treatment Outcome |
| title | The Negative Effect of Triple-Negative Breast Cancer on Outcome after Breast-Conserving Therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T21%3A49%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Negative%20Effect%20of%20Triple-Negative%20Breast%20Cancer%20on%20Outcome%20after%20Breast-Conserving%20Therapy&rft.jtitle=Annals%20of%20surgical%20oncology&rft.au=Zaky,%20Sandra%20S.&rft.date=2011-10-01&rft.volume=18&rft.issue=10&rft.spage=2858&rft.epage=2865&rft.pages=2858-2865&rft.issn=1068-9265&rft.eissn=1534-4681&rft_id=info:doi/10.1245/s10434-011-1669-4&rft_dat=%3Cproquest_cross%3E2449661011%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=888706217&rft_id=info:pmid/21442346&rfr_iscdi=true |